Topic: combination vaccines
Here is some other vaccine news of note for the week.
Instead of launching their new combination pediatric shot now, Sanofi and Merck will spend this year building up supplies for a 2020 rollout.
Takeda seeks delay of Velcade copy approvals, a new bid for Sinovac appears, Samsung and Biogen's Humira copycat gets EMA support.
With GlaxoSmithKline’s vaccines sales expanding, it figures it needs expanded production as well and some of that will happen at a 10-year-old plant in Hungary.
Having won FDA approval in May 2015, Sanofi Pasteur’s DTaP-IPV vaccine Quadracel is now available in the U.S. and ready to challenge GlaxoSmithKline’s Kinrix.
In a deal that could save millions of lives, the United Nations Children’s Fund has reached an unprecedented agreement with six manufacturers that slashes the price of pentavalent vaccine to half what the agency currently pays.